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Abstract
Background: Metastatic melanoma represents a major clinical problem. Its incidence continues to rise in western
countries and there are currently no curative treatments. While mutation of the P53 tumour suppressor gene is a
common feature of many types of cancer, mutational inactivation of P53 in melanoma is uncommon; however, its
function often appears abnormal.
Methods: In this study whole genome bead arrays were used to examine the transcript expression of P53 target
genes in extracts from 82 melanoma metastases and 6 melanoma cell lines, to provide a global assessment of
aberrant P53 function. The expression of these genes was also examined in extracts derived from diploid human
melanocytes and fibroblasts.
Results: The results indicated that P53 target transcripts involved in apoptosis were under-expressed in melanoma
metastases and melanoma cell lines, while those involved in the cell cycle were over-expressed in melanoma cell
lines. There was little difference in the transcript expression of P53 target genes between cell lines with null/
mutant P53 compared to those with wild-type P53, suggesting that altered expression in melanoma was not
related to P53 status. Similarly, down-regulation of P53 by short-hairpin RNA (shRNA) had limited effect on P53
target gene expression in melanoma cells, whereas there were a large number of P53 target genes whose mRNA
expression was significantly altered by P53 inhibition in melanocytes. Analysis of whole genome gene expression
profiles indicated that the ability of P53 to regulate genes involved in the cell cycle was significantly reduced in
melanoma cells. Moreover, inhibition of P53 in melanocytes induced changes in gene expression profiles that were
characteristic of melanoma cells and resulted in increased proliferation. Conversely, knockdown of P53 in
melanoma cells resulted in decreased proliferation.
Conclusions: These results indicate that P53 target genes involved in apoptosis and cell cycle regulation are
aberrantly expressed in melanoma and that this aberrant functional activity of P53 may contribute to the
proliferation of melanoma.
Background
Metastatic melanoma represents a major clinical pro-
blem. The incidence of melanoma continues to rise in
western countries, and because of its highly aggressive
clinical behaviour and resistance to a wide range of
therapies, there are currently no curative treatments
once the disease spreads beyond locoregional sites [1-3].
While mutation of the P53 tumour suppressor gene is a
common feature of many types of cancer [4], mutational
inactivation of P53 in melanoma is uncommon and
wild-type P53 is frequently expressed at high levels
[5-9]. Moreover, unlike other cancers, the expression of
wild-type P53 in melanoma appears to increase with
tumour progression and depth of tumour invasion and
is associated with worse prognostic features [5]. Thus,
as judged from the malignant nature of melanoma and
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DNA-damaging agents [1], wild-type P53 in melanoma
fails to function as a tumour suppressor.
In the normal cell, the tumour suppressor P53 plays a
critical role in determining cell fate and has been classi-
fied as the “guardian of the genome”.I nr e s p o n s et o
genotoxic stress, P53 may promote either cell cycle
arrest and DNA repair or apoptosis [10,11]. The out-
come of P53 activation- life or death - is primarily due
to its role in the transcriptional regulation of numerous
genes involved in these responses [12,13]. High through-
put chromatin immunoprecipitation (ChIP) analysis has
estimated that P53 can bind to and potentially regulate
the expression of around 500 to 1600 target genes
[14,15], exemplifying its importance as a transcriptional
regulator.
In human melanoma, P53 accumulates after genotoxic
stress and retains its transcriptional activity, suggesting
that signalling pathways upstream of P53 remain intact
and that it is at least partly functional and can respond
to stress [16-18]. However, it has also been reported
t h a tw i l d - t y p eP 5 3m a yb ea b e r r a n t l yp h o s p h o r y l a t e d
following ionising radiation (IR) and that there is a fail-
ure to promote cell cycle arrest or apoptosis, suggesting
that signalling pathways downstream of P53 may be
defective in melanoma [18]. A number of mechanisms
for inhibition of P53 function in melanoma cells have
been suggested, such as de-regulation of MDM2 and
MDM4, over-expression of Y box-binding protein 1
(YB-1), loss of P53 adaptor proteins [19,20] and our
own studies have suggested that P53 isoforms may be
involved [16]. However, the exact P53 target genes - the
ultimate effectors of P53 function - that become de-
regulated in melanoma as a result of aberrant P53 sig-
nalling and allow it to bypass an apoptotic response,
p r o m o t i n gr e s i s t a n c et ot r e a t m e n t ,r e m a i nt ob e
elucidated.
In this study, the mRNA expression of known P53 tar-
get genes were examined in metastatic melanoma and
melanoma cell lines and compared to normal cells using
w h o l eg e n o m eb e a da r r a y s .W er e p o r tt h a tal a r g ep r o -
portion of P53 target genes, predominantly involved in
apoptosis and cell cycle regulation, were significantly
altered in metastatic melanoma and melanoma cell
lines. Altered expression of these genes was not depen-
dent on P53 status. Moreover, inhibition of P53 expres-
sion in melanoma cell lines had limited effect on P53
target gene expression, suggesting that constitutive regu-
lation of P53 target gene expression is dampened in
melanoma. Inhibition of P53 in melanocytes induced
changes in P53 target gene expression that were charac-
teristic of melanoma cells and resulted in increased pro-
liferation. Conversely, knockdown of P53 in melanoma
cells resulted in decreased proliferation. These results
provide new information on the mRNA expression of
P53-regulated target genes that become de-regulated in




From February 2000 to December 2006, melanoma
metastases were collected from 82 patients attending the
Newcastle Melanoma Unit. The melanomas were
cleaned of surrounding tissue, cut into 2-3 mm frag-
ments and stored in vials in liquid nitrogen. Written
consent was given by the patients for collection of their
samples. This study complies with the Helsinki Declara-
tion and was approved by the Hunter New England
Health Research Ethics Committee (Approval No: 05/
02/09/3.02). There were 40 females (mean age 61.6 ±
12.7 years) and 42 males (mean age 58.3 ± 15.1 years)
in the study. The tissue was collected from the following
sites in females: subcutaneous - 11, lymph nodes - 10,
lung/liver - 7, bowel - 4, brain - 3, bone - 1 and occult -
4. The sites in males were: subcutaneous - 11, lymph
nodes - 19, lung/liver - 9, bowel - 2 and occult - 1.
Cell lines
The human melanoma cell lines Mel-RM, MM200,
IgR3, Me1007, Me4405 and Sk-Mel-28 have been
described previously [21]. Sk-Mel-28 had mutant P53
and Me4405 was null for P53 [16]. All melanoma cell
lines were cultured in DMEM containing 5% FCS (Com-
monwealth Serum Laboratories, VIC, Australia) and
maintained in exponential growth at 37°C and 5% CO2.
Melanocytes were purchased from Cascade Biologics
(OR, USA) and cultured in Medium 154 (Cascade Biolo-
gics). FLOW2000, WS-1 and HDF1314 fibroblasts were
cultured in DMEM containing 10% FCS (Common-
wealth Serum Laboratories).
Stable transduction of cell lines
Short hairpin RNA (shRNA) sequences to P53 or a con-
trol were expressed in the pSIH1-H1-copGFP (Copepod
green fluorescent protein) shRNA expression vector
(Systems Biosciences, CA, USA). The P53-directed
shRNA sequence corresponds to nucleotides 1026-1044
(Accession number NM_000546) [22]. The control
shRNA sequence 5’-TTAGAGGCGAGCAAGACTA-3’
showed no homology to any known human transcript.
Lentiviruses were produced in HEK293T cells using the
pSIH1-H1-copGFP shRNA expression vector (Systems
Biosciences) encased in viral capsid encoded by three
packaging plasmids as described previously [23]. Viruses
were concentrated as described previously [24]. Viral
titres were determined using 1 × 10
5 U2OS cells/well in
6-well plates, transduced with serial dilutions of the
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μg/ml; Sigma, NSW, Australia). Cells were harvested 48
hours post-transduction, analysed by flow cytometry for
copGFP expression and viral titre calculated.
To generate P53 silenced stable cell lines, Mel-RM,
IgR3 and melanocytes were transduced at an MOI of 10
with either a virus encoding P53 shRNA or control
shRNA. Cells were transduced twice with three days in
between each transduction. The efficiency of transduc-
tion was monitored with co-expression of copGFP and
was consistently over 95%. All cell lines tested negative
for the presence of replicative competent virus using the
Retrotek HIV-1 p24 antigen ELISA kit (ZeptoMetrix
Corporation, NY, USA).
RNA extraction, amplification, labelling and hybridisation
Total RNA was extracted from melanoma cell lines,
melanocytes and fibroblasts using the SV Total RNA
Isolation System Kit according to the manufacturers’
instructions (Promega, NSW, Australia) and from meta-
static melanoma tissues (2-3 mm
2) using Trizol reagent
(Invitrogen, VIC, Australia) and the RNeasy Kit (Qiagen,
VIC, Australia). The extracted RNA was amplified and
biotinylated using the TotalPrep RNA Amplification kit
according to the manufacturers’ instructions (Ambion,
TX, USA), then hybridised to Sentrix HumanRef-8
Expression Beadchips according to the manufacturers’
instructions (Illumina, CA, USA). The arrays were
scanned on a Bead Array Reader (Illumina).
Microarray analysis
The expression of 20,589 transcripts was analysed in the
metastatic melanoma and melanocyte cRNA samples
using Illumina Sentrix HumanRef-8 Expression Bead-
chips (v2.0, Illumina). The expression of 24,526 tran-
scripts was analysed in the cell line samples, using
Illumina Sentrix HumanRef-8 Expression Beadchips
(v3.0, Illumina). All samples were cubic spline normal-
ised using BeadStudio 3.0 software (Illumina) and nor-
malised to the median using GeneSpring GX v10.0
(Agilent Technologies, VIC, Australia). All subsequent
analysis was performed using GeneSpring GX v10.0
(Agilent Technologies).
Two-hundred and ninety probes, representing 247
unique transcripts and 181 unique target genes, identi-
fied through literature and database searches to either
be regulated by P53 or known to regulate P53 activity,
were used for further analysis (Additional file 1, Table
S1). Unpaired t-tests were used to identify P53 target
transcripts with significantly altered expression (p <
0.05) between melanoma and normal cells; and between
melanoma cells with mutant/null P53 compared to
those with wild-type P53.O n e - w a yA N O V Aw i t ha
post-hoc Tukey test was used to determine target genes
regulated by P53 inhibition in multiple cell lines. To
control for false positive results, Benjamini and Hoch-
berg False Discovery Rate (FDR) of 5.0% was used for
multiple testing. Genes that had more than 2 fold
increase or decrease in expression, a p-value equal to or
below 0.05 and an FDR that did not exceed 0.05 were
considered to be differentially expressed between the
two sample groups.
SOURCE [25] and PANTHER [26] were used to anno-
tate the biological processes and pathways that differen-
tially expressed genes were involved in. Differentially
expressed gene lists were compared to the PANTHER
reference list and to each other using the gene expression
analysis tool. This tool uses the binomial test for each
molecular function, biological process, or pathway term in
PANTHER, to statistically (p < 0.05) determine over- or
under-representation of PANTHER classification cate-
gories. A PANTHER category with a p-value equal to or
below 0.05 was considered to significantly over- or under-
represented. Supervised hierarchical cluster analysis was
performed on genes that were found to be significantly dif-
ferent (> 2 fold, p < 0.05). Similarity in the expression pat-
terns between genes was measured by Manhattan distance.
The results of this microarray analysis were deposited in
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.
nih.gov/geo/ with Accession No. GSE29377.
Western blot analysis
Protein extraction, separation by SDS-PAGE and wes-
tern blot analysis of cell lines to confirm inhibition of
P53 expression was performed as described previously
[16]. The mouse monoclonal antibodies used for the
detection of P53 (BP53-12) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) were purchased from
Upstate (NY, USA) and Ambion (TX, USA) respectively.
Real-time PCR
Total RNA (500 ng) was reverse transcribed to generate
cDNA using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, VIC, Australia)
according to the manufacturers’ instructions. Real-time
PCR analysis was performed in triplicate using Taq-
Man
® Universal PCR mix and TaqMan
® Gene Expres-
sion Assays (Applied Biosystems) according to the
manufacturers’ instructions, with results quantified on a
7500 real-time PCR system (Applied Biosystems). The
expression of the following transcripts was analysed:
CDC25C (Hs00156411_m1), BIRC5 (Hs00977611_g1),
CDKN2A (Hs00923894_m1), PLK2 (Hs01573415_g1),
SESN1 (Hs00205427_m1), BRCA1 (Hs01556191_m1)
and b-Actin (4326315E). The relative expression of the
gene of interest was normalised to b-Actin (DCt) and
expressed as the fold change calculated using the 2
-ΔΔCt
method [27].
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Colony formation and MTT assays were used to mea-
sure cellular proliferation and were performed as pre-
viously described [28].
Results
Transcript expression of P53 target genes in metastatic
melanoma
To determine genes involved in the P53 signalling path-
w a yt h a tw e r ea l t e r e di nm e tastatic melanoma, whole
genome bead arrays were used to analyse gene expres-
sion patterns in 82 metastatic melanomas compared to
8 diploid melanocyte strains, which were used as a nor-
mal control. A literature and database search identified
290 probes present on the arrays, representing 247
unique transcripts and 181 unique target genes that
were known to regulate or to be regulated by P53
(Additional file 1, Table S1), and these were further ana-
lysed between the two groups (metastatic melanoma
versus melanocytes). Fifty-six of the transcripts (56/290,
19.3%) were identified as being differentially expressed
between the metastatic melanomas and the melanocytes.
Supervised hierarchical clustering of these genes clearly
separated the melanocytes from the metastatic mela-
noma cases, suggesting that the mRNA expression of
these P53 target genes can discriminate these two
groups (Figure 1A).
Of the 56 significantly altered transcripts, 23 showed
increased expression and 33 showed decreased expres-
sion in metastatic melanomas when compared to mela-
nocytes (Table 1). Apoptosis and cell cycle were the
main P53-regulated biological processes altered in meta-
static melanoma, representing 23.2% (13/56) and 28.6%
(16/56) of the gene set respectively (Table 1). The
majority of transcripts (9/13, 69.2%) involved in apopto-
sis regulation were significantly decreased in metastatic
melanoma when compared to melanocytes and included
the Bcl-2 family members BAX and Bcl-xL (BCL2L1);
Caspases 6, 7 and 8; and the tumour necrosis factor
receptor superfamily member 10D (TRAIL-R4, DcR2)
(Table 1). The mRNA expression of several genes
involved in cell cycle control and/or proliferation,
including the Cyclins B3, E1, G1 and G2; PCNA and
RB1 were also decreased in metastatic melanoma (Table
1). Decreased expression of Cyclin D1 and RB1 proteins
has previously been reported in melanoma [5]. Several
genes involved in immunity and defense were highly
over-expressed in metastatic melanomas (Table 1). Of
these, the mRNA expression of THBS1 and THBS2 has
been inversely associated with melanoma growth and
progression [29,30], while CX3CL1 inhibition has been
shown to reduce melanoma growth and angiogenesis in
mice [31].
Transcript expression of P53 target genes in melanoma
cell lines
To determine whether altered regulation of P53 target
genes could be recapitulated in vitro, the mRNA expres-
sion of the 290 probes (Additional file 1, Table S1) were
examined in six melanoma cell lines, including four with
wild-type P53 (IgR3, Mel-RM, MM200, Me1007), one
with no P53 expression (Me4405) and one with mutant
P53 (Sk-Mel-28, G454A) [16]. The mRNA expression of
these genes in melanoma cells was compared to a mela-
nocyte cell line and two fibroblast strains (HDF1314,
FLOW2000), which served as normal controls. Thirty-
four transcripts (34/290, 11.72%) were significantly
altered in melanoma cells when compared to normal
cells (Table 2) and could clearly distinguish normal cells
from the melanoma cell lines in hierarchical cluster ana-
lysis (Figure 1B).
Of these transcripts, 9/34 (26.5%) were identified as
being differentially expressed in metastatic melanoma
patients when compared to melanocytes (Table 2).
Although some of these genes (e.g. cell cycle genes
CCND2, CCNE1 and PCNA) had fold changes that were
in a different direction when compared to metastatic
melanoma patients (Tables 1 and 2), this is likely to be
due to the active growth of these cells in culture. The
majority of transcripts found to be significantly different
in melanoma when compared to normal cells were
involved in apoptosis (8/34, 23.5%) or cellular prolifera-
tion and/or differentiation (16/34, 47.1%) (Table 2).
Overall, the mRNA expression of P53 target genes
involved in apoptosis was significantly decreased in mel-
anoma, while the mRNA expression of P53 target genes
involved in cell cycle regulation was significantly
increased (Table 2). These results suggest that the
mRNA expression profiles of P53-regulated target genes
and the P53-regulated biological processes that are
altered as a result of their changed expression are simi-
lar between metastatic melanoma patients and mela-
noma cell lines, further confirming the disruption of
P53-regulated apoptotic and cell cycle pathways in
melanoma.
The expression of these transcripts in cell lines with
wild-type P53 (IgR3, Me1007, Mel-RM, MM200) was
similar in the two cell lines which had null/mutant P53
expression, Me4405 and Sk-Mel-28, suggesting that
overall, their expression was not related to P53 status
(Figure 1B). In confirmation, the mRNA expression of
very few P53 target genes was found to be significantly
different between cell lines with wild-type P53 when
compared to cell lines with null/mutant P53 expression
(Table 3). The mRNA expression of Stromal antigen 1
(STAG1) and Survivin (BIRC5) was significantly higher
in cell lines with wild-type P53 compared to those with
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homolog 2 (SLUG), Cell division cycle 25C (CDC25C),
CD82 (KAI1) and P14ARF (CDKN2A) were expressed at
significantly lower levels (Table 3). Thus, these results
suggest that the expression or mutation status of P53 in
melanoma has little impact on the expression profile of
P53 target genes.
Inhibition of P53 has limited effect on the mRNA
expression of known P53 target genes in melanoma
To formally test the role of P53 in the regulation of these
P53-regulated transcripts, melanocytes and melanoma
cell lines (Mel-RM and IgR3) were generated in which
the expression of the P53 protein was stably inhibited
using shRNA. These were compared to cells which had
been stably transduced with a non-specific control
shRNA. Of the 290 transcripts analysed (Additional file
1, Table S1), inhibition of P53 expression resulted in dif-
ferential regulation of 19 (6.6%) transcripts in melano-
cytes. In melanoma cells, approximately half the number
of transcripts were shown to be significantly regulated by
P53 (7 (2.4%) in IgR3, 11 (3.8%) in Mel-RM), further sug-
gesting the lack of P53 regulation of common target
genes in melanoma (Table 4).
Only 3 genes, P21 (CDKN1A), Growth differentiation
factor 15 (GDF15) and Cytoplasmic FMR1 interacting
protein 2 (CYFIP2) were commonly regulated in mela-
nocytes and melanoma cells alike and the direction of
their regulation (i.e. increased transcript expression of
P21 in control shRNA transduced cells) was consistent
with their expected regulation by P53 (Table 4). Of
note, a high proportion of genes (16/19) that were regu-
lated by P53 in melanocytes were not regulated in mela-
noma cells. In particular, the mRNA expression of P53
Figure 1 The mRNA expression of P53 target genes is de-regulated in human melanoma. Supervised hierarchical cluster analysis was
performed on P53 target genes significantly altered between melanoma and melanocytes. Similarity in the mRNA expression patterns between
genes and between samples was measured using Manhattan distance. Distances between clusters represent the average distances between
genes and samples in the cluster. Genes are coloured according to their expression level, where up-regulated expression is represented by red,
down-regulated expression is represented by blue, and equal expression is represented by yellow. (A) Analysis of 56 differentially expressed
genes in 82 metastatic melanoma patients compared to 8 melanocyte cell lines. (B) Analysis of 34 differentially expressed genes in 6 melanoma
cell lines (IgR3, Mel-RM, Me1007, MM200, Sk-Mel-28, Me4405) compared to normal cells (melanocytes, FLOW2000, HDF1314).
Avery-Kiejda et al. BMC Cancer 2011, 11:203
http://www.biomedcentral.com/1471-2407/11/203
Page 5 of 17Table 1 P53 targets differentially expressed in melanoma metastases
No. Accession No. Gene Symbol Gene Name Fold change p-value
Apoptosis
1 NM_001040619.1 ATF3 Activating transcription factor 3, transcript variant 4 4.62 0.0042
2 NM_003879.3 CFLAR/FLIP CASP8 and FADD-like apoptosis regulator 3.10 0.0063
3 NM_004324.3 BAX BCL2-associated X protein, transcript variant beta -3.92 0.0127
4 NM_138578.1 BCL2L1 BCL2-like 1 (Bcl-xL), transcript variant 1 -5.77 0.0144
5 NM_001226.3 CASP6 Caspase 6, transcript variant alpha -13.07 4.98E-05
6 NM_033340.2 CASP7 Caspase 7, transcript variant beta -3.69 0.0465
7 NM_001080125.1 CASP8 Caspase 8, transcript variant G -11.38 2.28E-05
8 NM_033356.3 CASP8 Caspase 8, transcript variant C -2.96 0.0273
9 NM_001007277.1 EI24 Etoposide induced 2.4 mRNA, transcript variant 2 -2.81 0.0245
10 NM_021127.1 PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 (Noxa) 12.18 0.0063
11 NM_000314.4 PTEN Phosphatase and tensin homolog -3.29 0.0062
12 NM_003840.3 TNFRSF10D Tumor necrosis factor receptor superfamily, member 10d -29.89 8.37E-07
13 NM_004881.2 TP53I3 Tumor protein p53 inducible protein 3, transcript variant 1 -4.50 0.0097
Cell cycle, proliferation and differentiation
14 NM_033031.2 CCNB3 Cyclin B3, transcript variant 3 -8.38 1.47E-04
15 NM_033031.2 CCNB3 Cyclin B3, transcript variant 3 -10.79 1.18E-04
16 NM_001759.2 CCND2 Cyclin D2 76.10 1.73E-07
17 NM_001238.1 CCNE1 Cyclin E1, transcript variant 1 -7.61 2.07E-10
18 NM_057749.1 CCNE2 Cyclin E2 3.54 0.0476
19 NM_199246.1 CCNG1 Cyclin G1, transcript variant 2 -5.75 0.0146
20 NM_004354.1 CCNG2 Cyclin G2 -10.66 2.10E-04
21 NM_001798.2 CDK2 Cyclin-dependent kinase 2, transcript variant 1 -4.09 0.0476
22 NM_001798.2 CDK2 Cyclin-dependent kinase 2, transcript variant 1 -17.99 0.0017
23 NM_058197.3 CDKN2A Cyclin-dependent kinase inhibitor 2A, transcript variant 3 4.97 0.0202
24 NM_058195.2 CDKN2A Cyclin-dependent kinase inhibitor 2A, transcript variant 4 -7.09 0.0351
25 NM_015675.2 GADD45B Growth arrest and DNA-damage-inducible, beta 7.41 0.0020
26 NM_006705.2 GADD45G Growth arrest and DNA-damage-inducible, gamma 11.13 0.0154
27 NM_002592.2 PCNA Proliferating cell nuclear antigen, transcript variant 1 -7.25 4.32E-04
28 NM_182649.1 PCNA Proliferating cell nuclear antigen, transcript variant 2 -4.53 0.0219
29 NM_000321.2 RB1 Retinoblastoma 1 -5.85 0.0097
DNA repair
30 NM_138292.3 ATM Ataxia telangiectasia mutated, transcript variant 2 4.49 0.0328
31 NM_007306.2 BRCA1 Breast cancer 1, early onset, transcript variant BRCA1-exon4 -3.56 0.0371
Immunity and defense
32 NM_001024844.1 CD82 CD82 molecule, transcript variant 2 -4.80 0.0127
33 NM_002996.3 CX3CL1 Chemokine (C-X3-C motif) ligand 1 9.44 2.67E-05
34 NM_153201.1 HSPA8 Heat shock 70kDa protein 8, transcript variant 2 -3.47 0.0350
35 NM_006597.3 HSPA8 Heat shock 70kDa protein 8, transcript variant 1 -3.31 0.0100
36 NM_001098631.1 IRF5 Interferon regulatory factor 5, transcript variant 7 13.39 3.78E-04
37 NM_182826.1 SCARA3 Scavenger receptor class A, member 3, transcript variant 2 6.60 0.0139
38 NM_003246.2 THBS1 Thrombospondin 1 81.54 1.31E-08
39 NM_003247.2 THBS2 Thrombospondin 2 4.16 0.0408
Metabolism
40 NM_020128.1 MDM1 Mdm4, transformed 3T3 cell double minute 1, transcript variant 2 -3.98 0.0146
41 NM_020128.1 MDM1 Mdm4, transformed 3T3 cell double minute 1, transcript variant 2 7.64 0.0023
42 NM_004530.2 MMP2 Matrix metallopeptidase 2 -12.58 0.0017
43 NM_000603.3 NOS3 Nitric oxide synthase 3 11.77 4.62E-05
44 NM_033239.2 PML Promyelocytic leukemia, transcript variant 9 -6.24 2.81E-04
45 NM_001034.1 RRM2 Ribonucleotide reductase M2 polypeptide -3.38 0.0476
46 NM_005063.4 SCD Stearoyl-CoA desaturase -4.04 0.0039
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dominantly altered by P53 inhibition in melanocytes and
these genes showed a complete lack of regulation by
P53 in melanoma cell lines (Table 4). Many of the P53
target genes involved in cell cycle regulation (5/9 genes,
Table 4) that were altered by P53 inhibition in melano-
cytes but not in melanoma, were over-expressed in mel-
anoma when compared to normal cells (Table 2).
Notably, the mRNA expression of CDKN2A and BIRC5
(shown to be altered in P53 mutant melanoma cells)
was significantly lower in melanocytes expressing con-
trol shRNA, suggesting that the inhibitory effect of P53
expression on these genes was relieved in cells expres-
sing P53 shRNA (Table 4). However, P53 inhibition had
no effect on CDKN2A or BIRC5 transcript expression in
melanoma cells (Table 4), confirming de-regulated sig-
nalling by P53 in these cells. The lack of P53-dependent
regulation of its target genes in melanoma was not due
to a failure to inhibit this protein, given that P53 expres-
sion was shown to be almost completely abolished in
cells transduced with P53 shRNA (Figure 2A). More-
over, the altered P53-dependent transcriptional regula-
tion of 4 genes ( B I R C 5 ,C D C 2 5 C ,P L K 2and SESN1) in
melanoma compared to melanocytes was confirmed by
real-time PCR (Figure 2B). In addition, we have pre-
viously shown that endogenous and over-expressed P53
can regulate the transcription of the P21 and PUMA
promoters in luciferase assays [16] and in this study,
both the basal and cisplatin-induced protein expression
of P21 was abolished in IgR3 and Mel-RM cells in
which P53 had been inhibited (Additional file 2, Figure
S1), demonstrating that P53 in these cells is transcrip-
tionally competent. Taken together, these results suggest
that the constitutive transcriptional regulation of known
P53 target genes involved in the cell cycle is consider-
ably dampened in melanoma.
Inhibition of P53 in melanocytes results in an altered P53
target gene mRNA expression profile that is similar to
that observed in melanoma cells
Hierarchical cluster analysis of the 13 genes that were
only regulated by P53 in melanoma cells and not in mela-
nocytes (Table 4) could not distinguish melanoma cells
that had been transduced with P53 shRNA from mela-
noma cells that had been transduced with control shRNA
(Figure 2C). However, hierarchical cluster analysis of the
16 genes that were significantly regulated by P53 only in
melanocytes and not in melanoma cells (Table 4), clearly
separated the cell lines into two distinct groups (Figure
2D). Melanocytes that had been transduced with control
shRNA formed one branch of the dendrogram, while
melanocytes that had been transduced with P53 shRNA
formed another branch that was more closely related to
all of the melanoma cell lines (regardless of P53 expres-
sion) than it was to melanocytes transduced with control
shRNA (Figure 2D). These results suggest that transcrip-
tional control of key P53 target genes (mostly involved in
cell cycle) by P53 in melanocytes is necessary for normal
function and that disrupted transcriptional regulation of
these target genes (by inhibition of P53) can induce gene
expression profiles that are similar to that observed in
melanoma cells.
The ability of P53 to regulate genes involved in the cell
cycle is significantly reduced in melanoma cells
Given that P53 in melanoma cells failed to regulate typi-
cal P53 target genes when compared to melanocytes, we
next determined the effect of P53 knockdown on whole
genome gene expression profiles. Of the 24,526 tran-
scripts analysed, inhibition of P53 expression resulted in
differential regulation of 728 (2.97%) transcripts in mela-
nocytes. In melanoma cells, fewer transcripts were shown
to be significantly regulated by P53; 591 transcripts
Table 1 P53 targets differentially expressed in melanoma metastases (Continued)
Transcription regulation
47 NM_006210.1 PEG3 Paternally expressed 3 42.85 2.28E-05
48 NM_003068.3 SNAI2/SLUG Snail homolog 2 -27.69 9.45E-07
49 NM_004295.3 TRAF4 TNF receptor-associated factor 4 3.75 0.0033
50 NM_152240.1 ZMAT3/WIG1 Zinc finger, matrin type 3, transcript variant 2 -6.97 0.0024
Signal transduction
51 NM_014376.2 CYFIP2 Cytoplasmic FMR1 interacting protein 2, transcript variant 3 17.86 1.20E-08
52 NM_004431.2 EPHA2 EPH receptor A2 5.42 0.0031
53 NM_001005914.1 SEMA3B Semaphorin 3B, transcript variant 2 156.75 1.59E-08
Unknown function
54 NM_012242.2 DKK1 Dickkopf homolog 1 -17.41 0.0097
55 NM_182915.2 STEAP3 STEAP family member 3, transcript variant 1 8.22 0.0024
56 NM_005802.2 TOPORS Topoisomerase I binding, arginine/serine-rich -4.13 0.0350
Fold change in mRNA expression of P53 target genes found to be significantly different in extracts from 82 metastatic melanomas compared to extracts from 8
melanocyte cell lines (> 2-fold difference, p < 0.05 and a false discovery rate (FDR) = 5.0%).
Avery-Kiejda et al. BMC Cancer 2011, 11:203
http://www.biomedcentral.com/1471-2407/11/203
Page 7 of 17Table 2 P53 targets differentially expressed in melanoma cells
No. Accession No. Gene Symbol Gene Name Fold change p-value
Apoptosis
Induction of apoptosis
1 NM_138765.2 BAX BCL2-associated X protein, transcript variant sigma -4.19 0.0062
2 NM_004324.3 BAX
1 BCL2-associated X protein, transcript variant beta -4.67 0.0059
3 NM_001225.3 CASP4 Caspase 4, transcript variant alpha -2.32 0.0027
4 NM_001226.3 CASP6
1 Caspase 6, transcript variant alpha 3.17 0.0401
5 NM_021202.1 TP53INP2 Tumor protein p53 inducible nuclear protein 2 -3.02 0.0034
6 NM_147184.1 TP53I3/PIG3 Tumor protein p53 inducible protein 3, transcript variant 2 -3.67 0.0031
Inhibition of apoptosis
7 NM_138578.1 BCL2L1
1 B-cell CLL/lymphoma 2-like 1, transcript variant 1 -2.95 0.0124
8 NM_003840.3 TNFRSF10D
1 Tumor necrosis factor receptor superfamily, member 10d -33.80 0.0005
Cell cycle, proliferation and differentiation
9 NM_001012271.1 BIRC5 Baculoviral IAP repeat-containing 5 (Survivin), transcript variant 3 4.60 0.0024
BIRC5 12.61 1.8E-05
10 NM_031966.2 CCNB1 Cyclin B1 18.17 0.0005
11 NM_001759.2 CCND2
1 Cyclin D2 -75.73 0.0427
12 NM_001238.1 CCNE1
1 Cyclin E1, transcript variant 1 2.34 0.0310
13 NM_057735.1 CCNE2 Cyclin E2, transcript variant 2 9.33 0.0198
14 NM_001786.2 CDC2/CDK1 Cell division cycle 2, transcript variant 1 6.32 0.0127
15 NM_001790.3 CDC25C Cell division cycle 25 homolog C, transcript variant 1 17.05 0.0020
16 NM_001790.3 CDC25C Cell division cycle 25 homolog C, transcript variant 1 15.26 0.0001
17 NM_022809.2 CDC25C Cell division cycle 25 homolog C, transcript variant 2 13.39 0.0011
CDC25C 18.21 0.0004
18 NM_058197.3 CDKN2A
1 Cyclin-dependent kinase inhibitor 2A, transcript variant 3 3.14 0.0472
CDKN2A 1.56 0.4706
19 NM_001274.3 CHEK1 CHK1 checkpoint homolog 3.14 0.0105
20 NM_016426.4 GTSE1 G-2 and S-phase expressed 1 6.69 0.0014
21 NM_182649.1 PCNA
1 Proliferating cell nuclear antigen, transcript variant 2 4.66 0.0397
22 NM_006034.2 TP53I11 Tumor protein p53 inducible protein 11 -54.31 2.31E-06
DNA repair
23 NM_007304.2 BRCA1 Breast cancer 1, transcript variant BRCA1-delta11b 3.70 0.0092
24 NM_007299.2 BRCA1 Breast cancer 1, transcript variant BRCA1-delta14-17 3.06 0.0068
BRCA1 5.47 0.0037
Immunity and defense
25 NM_000963.1 PTGS2 Prostaglandin-endoperoxide synthase 2 -15.59 0.0074
Metabolism
26 NM_201397.1 GPX1 Glutathione peroxidase 1, transcript variant 2 -2.16 0.0011
27 NM_004530.2 MMP2 Metallopeptidase 2 -6.61 0.0296
28 NM_001034.1 RRM2
1 Ribonucleotide reductase M2 polypeptide 10.48 0.0068
Signal Transduction
29 NM_000623.2 BDKRB2 Bradykinin receptor B2 -16.54 0.0040
Transport
30 NM_002539.1 ODC1 Ornithine decarboxylase 1 4.12 0.0099
31 NM_018976.3 SLC38A2 Solute carrier family 38, member 2 -5.03 0.0074
Biological function unclassified
32 NM_018685.2 ANLN Anillin 8.88 4.17E-06
33 XM_001133677.1 LOC729264 PREDICTED: Similar to TP53TG3 protein, transcript variant 2 25.41 0.0068
34 NM_016212.2 TP53TG3 Tumor protein p53 target gene 3 102.59 0.0005
Fold change in mRNA expression of 34 P53 target genes found to be significantly different in melanoma cell lines (IgR3, Mel-RM, MM200, Me1007, Me4405, Sk-
Mel-28) compared to normal cell lines (melanocytes, FLOW2000, HDF1314) (> 2-fold difference, p ≤ 0.05 and FDR = 5.0%). Real-time qRT-PCR verification of
selected genes is shown in italics.
1Genes found to be differentially expressed between metastatic melanoma patients and melanocytes.
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Hierarchical clustering of the 728 transcripts regulated
by P53 in melanocytes showed that very few of these tar-
get genes were regulated in the IgR3 and Mel-RM mela-
noma cell lines by P53 (Figure 3A). Furthermore,
following P53 knockdown the expression of these tran-
scripts in melanocytes was highly similar to the expres-
sion of these transcripts in melanoma cells, where two
distinct groupings were seen in hierarchical clustering.
Melanocytes that had been transduced with control
shRNA formed one group, while melanoma cell lines and
melanocytes with inhibited P53 expression formed
another group (Figure 3A and 3B). These results further
confirmed that disrupted regulation of P53 signalling in
melanocytes can induce gene expression profiles that are
similar to those observed in melanoma cells.
To determine the biological processes that were signif-
icantly altered by P53 knockdown, the gene ontologies
of the significantly regulated genes (control shRNA ver-
sus P53 shRNA) in each of the cell lines were analysed
in PANTHER [26]. Mitosis, cellular processes, cell cycle,
cytokinesis and nucleic acid metabolism were the 5
most significantly up-regulated processes in melanocytes
(Table 5). Cellular processes were also significantly up-
regulated in both melanoma cell lines, while mitosis and
cell cycle were significantly up-regulated in Mel-RM and
IgR3 cells respectively (Table 5). These results are con-
cordant with a recent study conducted by Terzian and
colleagues who found that activation of P53 by Nutlin
in primary melanocytes repressed the expression of
genes involved in cell cycle progression, DNA replica-
tion and chromosomal maintenance [32]. We next
determined whether the biological processes regulated
by P53 knockdown in melanoma cell lines were different
to those that were regulated by P53 knockdown in mela-
nocytes. Genes involved in mitosis, cell cycle, cytokinesis
and nucleic acid metabolism were significantly under-
represented in both Mel-RM and IgR3 cell lines when
compared to melanocytes (Table 5 and Figure 3C). In
addition, while the majority of transcripts involved in
mitosis, cell cycle and cytokinesis were down-regulated
in control shRNA melanocytes when compared to P53
knockdown melanocytes, the majority of genes regulated
by P53 in these categories were up-regulated in mela-
noma cells (compare grey and black proportion of the
bar graph in Figure 3C). This suggests that both the
number of genes regulated by P53 and the direction of
their regulation is significantly altered in melanoma cells
when compared to melanocytes.
Taken together, these results suggest that P53 knock-
down in melanocytes induced changes in gene expres-
sion patterns that were similar to the gene expression
patterns in melanoma cells. Furthermore, many of the
target genes that were regulated by P53 in melanocytes
were unaffected in melanoma cells and in particular, the
ability of P53 to regulate genes involved in cell cycle
functions was significantly reduced in melanoma cells
when compared to melanocytes.
Inhibition of P53 increases proliferation in normal cells,
but reduces proliferation in melanoma
Our gene expression data suggested that P53-dependent
transcriptional control of target genes predominantly
involved in cell cycle regulation was disrupted in mela-
noma when compared to melanocytes. Hence, to deter-
mine the effect of P53 on proliferation, we performed
MTT and colony formation assays in cells transduced
with either control shRNA or P53 shRNA. In melano-
cytes, the long-term reduction in P53 (greater than 4
weeks post-transduction) resulted in an overall increase
in proliferation and an increased proliferation rate (mea-
sured as the gradient of each of the lines, 37.6 fold
increase) when compared to cells that had been trans-
duced with control shRNA (Figure 4A). The same effect
was observed in WS-1 and HDF1314 fibroblasts (Figure
4A and data not shown). However, inhibition of P53 in
melanoma cells reduced overall proliferation and the
proliferation rate (-2.66 fold reduction in IgR3 cells and
Table 3 P53 target genes differentially expressed in melanoma cells with wild-type or mutant P53
Accession No. Gene Symbol Gene Name Fold change (WT vs MT) p-value
NM_001012271.1 BIRC5 Baculoviral IAP repeat-containing 5 (Survivin), transcript variant 3 2.81 0.03297
BIRC5 2.42 0.01001
NM_001080125.1 CASP8 Caspase 8, transcript variant G -5.88 0.02569
NM_001024844.1 CD82 CD82 molecule, transcript variant 2 -19.52 0.03576
NM_001790.3 CDC25C Cell division cycle 25 homolog C, transcript variant 1 -2.57 0.00007
NM_058195.2 CDKN2A Cyclin-dependent kinase inhibitor 2A, transcript variant 4 -88.58 0.0159
CDKN2A -34.08 2.2E-05
NM_003068.3 SNAI2/SLUG Snail homolog 2 -8.92 0.00005
NM_005862.2 STAG1 Stromal antigen 1 2.33 0.04536
Fold change in mRNA expression of p53 target genes found to be significantly different in extracts from melanoma cell lines expressing wild-type p53 (IgR3, Mel-
RM, MM200, Me1007) compared to melanoma cell lines with null/mutant p53 (Sk-Mel-28, Me4405) (> 2-fold difference, p ≤ 0.05 and FDR = 5.0%). Real-time qRT-
PCR verification of selected genes is shown in italics.
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Accession No. Gene Symbol Gene Name Melan. IgR3 Mel-RM
Genes regulated similarly by p53 KO in melanocytes and melanoma cells
Cell cycle, proliferation or differentiation
NM_000389.2 CDKN1A Cyclin-dependent kinase inhibitor 1A, transcript variant 1 2.68 - 7.12
NM_004864.1 GDF15 Growth differentiation factor 15 3.42 - 6.11
Transcription regulation/signal transduction
NM_014376.2 CYFIP2 Cytoplasmic FMR1 interacting protein 2, transcript variant 3 5.11 - 8.88
Genes regulated by p53 KO in melanoma cells but not in melanocytes
Apoptosis
NM_138578.1 BCL2L1
1 BCL2-like 1 (Bcl-xL), transcript variant 1 - -2.06 2.01
NM_033294.2 CASP1 Caspase 1, transcript variant delta - - -4.20
NM_016479.3 SHISA5 Shisa homolog 5 - -2.30 -
NM_019058.2 DDIT4 DNA-damage-inducible transcript 4 - -2.56 -
Cell cycle, proliferation or differentiation
NM_078467.1 CDKN1A Cyclin-dependent kinase inhibitor 1A, transcript variant 2 - - 7.56
NM_000548.3 TSC2 Tuberous sclerosis 2, transcript variant 1 - - 3.95
Immunity and defense
NM_003897.3 IER3 Immediate early response 3 - - 2.59
Metabolism
NM_000603.3 NOS3 Nitric oxide synthase 3 -2.72 10.65 -
Transcription regulation/signal transduction
NM_001037333.1 CYFIP2 Cytoplasmic FMR1 interacting protein 2, transcript variant 1 - - 14.63
NM_152546.1 SRFBP1 Serum response factor binding protein 1 - - -2.12
NM_004559.3 YBX1 Y box binding protein 1 - -2.75 -
Transport
NM_000593.5 TAP1 Transporter 1 - 2.07 -
Unknown function
NM_182915.2 STEAP3 STEAP family member 3, transcript variant 1 - 4.64 -2.94
Genes regulated by p53 KO in melanocytes but not in melanoma
Apoptosis
NM_001040619.1 ATF3 Activating transcription factor 3, transcript variant 4 -5.30 --
NM_001008925.1 RCHY1 Ring finger and CHY zinc finger domain containing 1, transcript variant 2 -12.23 --
NM_005427.1 TP73 Tumor protein p73 10.54 - 2.84
Cell cycle, proliferation or differentiation
NM_001012271.1 BIRC5
1 Baculoviral IAP repeat-containing 5, transcript variant 3 -18.95 --
NM_004701.2 CCNB2 Cyclin B2 -3.17 --
NM_057735.1 CCNE2
1 Cyclin E2, transcript variant 2 -5.73 --
NM_001786.2 CDC2
1 Cell division cycle 2, transcript variant 1 -8.42 --
NM_022809.2 CDC25C
1 Cell division cycle 25 homolog C, transcript variant 2 -9.40 --
NM_001259.5 CDK6 Cyclin-dependent kinase 6 2.15 --
NM_058195.2 CDKN2A
1 Cyclin-dependent kinase inhibitor 2A, transcript variant 4 -12.78 --
NM_006622.2 PLK2 Polo-like kinase 2 18.00 -8.19 -
NM_014454.1 SESN1 Sestrin 1 2.69 --
Immunity and defense
NM_003246.2 THBS1 Thrombospondin 1 -18.25 --
NM_003247.2 THBS2 Thrombospondin 2 2.21 --
NM_033550.3 TP53RK TP53 regulating kinase -2.08 --
Transcription regulation/signal transduction
NM_000376.2 VDR Vitamin D receptor, transcript variant 1 -20.88 --
Fold change in mRNA expression of P53 targets genes regulated in melanocyte (Melan.), IgR3 or Mel-RM cell lines in which P53 expression had been inhibited
compared to cells expressing normal levels of P53 (control shRNA versus P53 shRNA). Genes that were significantly different (> 2-fold change, p ≤ 0.05 and FDR
= 5.0%) in comparisons of control shRNA with P53 shRNA are shown in bold, while genes which were not regulated (< 2-fold change) are represented by a
hyphen (-).
1Genes found to be differentially expressed between melanoma cells and normal cells.
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Page 10 of 17Figure 2 Inhibition of P53 expression by shRNA alters regulation
of P53 target genes. (A) Protein (25 μg) from melanocytes, WS-1,
Mel-RM and IgR3 cells that had been stably transduced with P53
shRNA or control shRNA was analysed for the expression of P53 by
western blotting. The expression of GAPDH was determined to ensure
equal loading. Arrowhead indicates expected molecular weight. (B)
Relative quantification of BIRC5, CDC25C, PLK2 and SESN1 mRNA by
real-time RT-PCR in melanocytes, Mel-RM and IgR3 cells that had been
stably transduced with P53 shRNA or control shRNA. Results are shown
as the relative normalised expression (target/b-Actin) of the target
gene in cells transduced with control shRNA compared to cells
transduced with P53 shRNA (2
-ΔΔCt). Values represent the mean ± SE.
(C) Supervised hierarchical cluster analysis of 13 genes that were
regulated by P53 in melanoma cells only and not in melanocytes.
Genes are coloured according to their expression level, where up-
regulated expression is represented by red, down-regulated expression
is represented by blue, and equal expression is represented by yellow.
(D) Supervised hierarchical cluster analysis of 16 genes that were
regulated by P53 in melanocytes only and not in melanoma cells.
Genes are coloured according to their expression level, where up-
regulated expression is represented by red, down-regulated expression
is represented by blue, and equal expression is represented by yellow.
Figure 3 Ability of P53 to regulate genes involved in cell cycle
is significantly reduced in melanoma. (A) Supervised hierarchical
cluster analysis of 728 genes that were significantly regulated by
P53 in melanocytes. The relative mRNA expression of these genes in
melanocytes, Mel-RM and IgR3 cells that had been stably
transduced with either P53 shRNA or control shRNA is shown. (B)
Supervised hierarchical cluster analysis of 728 genes that were
significantly regulated by P53 in melanocytes. The relative mRNA
expression of these genes in melanocytes that had been stably
transduced with either P53 shRNA or control shRNA compared to
IgR3, Mel-RM, SkMel-28, MM200, Me4405, and Me1007 melanoma
cell lines is shown. Genes are coloured according to their expression
level, where up-regulated expression is represented by red, down-
regulated expression is represented by blue, and equal expression is
represented by yellow. (C) The number of genes regulated by P53
(control shRNA versus P53 shRNA) in melanocytes, IgR3 and Mel-RM
cell lines in the biological process categories: nucleic acid
metabolism, cell cycle, cytokinesis and mitosis as defined by
PANTHER [26]. Up-regulated genes are shown in black while down-
regulated genes are shown in grey. The number of genes regulated
are also depicted as percentages of the total gene list on the bar
graph for each of the cell lines. The significance of the regulation of
these biological processes by P53 in each of the melanoma cell
lines (Mel-RM and IgR3) compared to melanocytes was determined
using the gene expression tool in PANTHER (
+p < 0.0005,
++p=
0.000003, *p < 0.05, **p < 0.005).
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cell line, when compared to cells that had been trans-
duced with control shRNA (Figure 4B). The long term
growth potential of melanoma cell lines with P53
silenced was also significantly inhibited when compared
to their control counterparts as determined by colony
formation assays (Figure 4C and 4D). This suggests that
the ability of wild-type P53 to inhibit cell growth in mel-
anoma is disrupted when compared to normal cells,
consistent with our gene expression analysis.
Discussion
Although P53 is not commonly mutated in metastatic
melanoma and can transcriptionally activate certain tar-
get genes in response to stress [5,17,18], its function is
abnormal as reflected by a failure to induce cell cycle
arrest and apoptosis [1,18]. In this study, we have exam-
ined the mRNA expression profile of known P53 target
genes and regulators in a large number of melanoma
metastases and cultured melanoma cell lines compared
to normal melanocytes and fibroblasts to provide a glo-
bal assessment of P53 functional aberration in
melanoma.
P53 target genes involved in apoptosis and cell cycle
regulation accounted for the large majority of tran-
scripts altered in metastatic melanoma tumours and
melanoma cell lines when compared to normal cells.
In melanoma tissue extracts, P53 target genes involved
in apoptosis were down-regulated compared to mela-
nocytes; the exception being genes for FLIP (inhibitor
of Caspase 8), PMAIP1 (Noxa, BH3 pro-apoptotic pro-
tein) and the ATF3 transcription factor (transcript var-
iant 4 or deltaZip2) which can counteract
transcriptional repression by full-length ATF3 [33].
Many cell cycle genes were also down-regulated, with
the exception of the growth arrest and DNA damage
inducible genes and a variant of CDKN2A (transcript
variant 3). Cyclin D2, involved in cell cycle transition
from G1 to S was also particularly high. These findings
are supported by a recent study by Yu and colleagues
who showed that benign nevi can be separated from
melanomas on the basis of their P53 target gene
expression profiles [34]. Of the 25 targets they identi-
fied as being consistently significantly different in two
separate datasets of melanoma compared to nevi,
almost half of the transcripts (9/25, 36%) were involved
in cell cycle regulation or apoptosis further confirming
our findings that these P53-dependent pathways are
dysregulated in metastatic melanoma. However, in
contrast to our analysis the majority of these tran-
scripts showed increased mRNA expression in mela-
noma when compared to nevi and this discrepancy
may be due to the imperfect comparison of melano-
cytes versus metastatic melanomas in our study [34].
In contrast to the studies on melanoma tissue, several
cell cycle regulatory genes had significantly increased
mRNA expression in melanoma lines reflecting their
proliferative state. In particular, the cell cycle proteins
BRCA1 and CHEK1 are capable of phosphorylating P53
and modulating its transcriptional activity [35-37]. Our
previous studies (on the melanoma cell lines used in
this study) have shown that P53 protein levels were
much higher in melanoma cells than compared to mela-
nocytes [16]. However, the expression of P53 target
genes involved in apoptosis was generally much lower in
melanoma cell lines compared to that in normal cells
(for example BAX is normally increased by P53, but
showed decreased expression in melanoma) and sug-
gests that P53 signalling is aberrant in melanoma.
Whether the increased expression of BRCA1 and
CHEK1 may account for the increased expression of cell
cycle genes and decreased expression of apoptotic target
genes in melanoma is yet to be determined.
The studies on melanoma cell lines were surprising in
that they revealed very few differences in P53 target
gene expression between P53 null/mutant cell lines and
those with wild-type P53, indicating that the constitutive
regulation of these P53 target genes was not related to
P53 status. Two of the genes that differed between these
cell lines were, CDKN2A which encodes P14ARF and
BIRC5 which encodes Survivin. These genes were also
expressed significantly higher in melanoma cell lines
when compared to normal cells. P14ARF enhances P53
functional activity by inhibiting MDM-2 mediated
repression of P53 [38] and inactivation of CDKN2A is a
common and critical event in the genesis of melanoma
[39]. However, the CDKN2A locus was shown to be
highly over-expressed in P53 null/mutant melanoma
cells in this study, perhaps due to loss of feedback inhi-
bition by P53 given that P53 can mediate transcriptional
inhibition of CDKN2A [38]. Survivin is over-expressed
in almost all human malignancies, including melanoma
[40], consistent with its higher expression in melanoma
cell lines observed in this study. Survivin is normally
repressed by P53 in human melanocytes [41] as shown
i nt h ec u r r e n ts t u d y( T a b l e4 ) ,b u tw a ss h o w nt ob e
down-regulated in melanoma cell lines with null/mutant
P53 when compared to those with wild-type P53 and
was not altered by inhibition of P53 expression in mela-
noma, further suggesting aberrant transcriptional regula-
tion of this target gene by P53 in melanoma.
To further examine the transcriptional regulation of
P53 target genes, P53 expression was down-regulated by
shRNA in melanocytes and two melanoma cell lines.
Silencing of P53 resulted in significant changes in the
mRNA expression of 19 P53 target genes in melanocytes
and several of these target genes have previously been
shown to be regulated by Nutlin activation of P53 in
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However, far fewer genes underwent significant changes
in melanoma cell lines (IgR3-7 genes and Mel-RM-11
genes). Similar results were observed when whole gen-
ome gene expression was compared. These studies con-
firmed that the constitutive mRNA expression of many
targets that were regulated by P53 in melanocytes were
unaffected in melanoma, suggesting that P53 had lost
the ability to regulate the expression of these transcripts
in melanoma. In particular, there were several cell cycle
genes whose transcription was increased by P53 inhibi-
tion in melanocytes (down-regulated in control shRNA
cells) that showed a complete lack of P53-dependent
regulation in melanoma cells. Given that many of these
Table 5 Gene ontologies regulated by P53 knockdown
Biological Process % of genes



































































































































































Analysis of the top 20 biological processes regulated by P53 knockdown (control shRNA versus P53 shRNA) in melanocytes (Melan.) compared to IgR3 and Mel-
RM cell lines using the PANTHER database and gene expression analysis tool [26]. The data are represented as the percentage of genes regulated in each
category from the entire gene list (> 2-fold change, p ≤ 0.05, FDR = 5.0% in comparisons of control shRNA with P53 shRNA) for each cell line. P-values for
biological processes that were significantly over or under represented (+/-) in comparisons of the gene lists between P53-regulated genes (from Melanocytes,
IgR3 or Mel-RM) and the human reference list are shown in the table, while biological processes that were significantly different (p < 0.05) between melanocytes
and either of the melanoma cell lines are highlighted in bold.
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when compared to normal cells (Table 2), this indicates
that aberrant P53 signalling may play a role in the
altered transcript expression of these genes and further
suggests that P53-dependent pathways are disrupted in
melanoma. Moreover, the ability of P53 to differentially
regulate target genes involved in cell cycle function was
confirmed in whole genome gene expression analysis,
further emphasising this aberrant functional activity of
P53.
Loss of P53 expression in mice and in human melano-
cytes has been shown to increase the proliferation and in
vivo tumourigenicity, concordant with the role of P53 as a
tumour suppressor [34,42]. An unexpected finding of this
study was that inhibition of P53 function in melanocytes
induced changes in gene expression profiles that were
Figure 4 Inhibition of P53 reduces proliferation in melanoma cells. (A) Proliferation was analysed in melanocytes and WS-1 fibroblasts that
had been stably transduced with P53 shRNA or control shRNA over a 72 hour period using the MTT assay. Results are represented as the mean
± SE of 3 experiments. (B) Proliferation was analysed in IgR3 and Mel-RM cells that had been stably transduced with P53 shRNA or control
shRNA over a 72 hour period using the MTT assay. Results are represented as the mean ± SE of 3 experiments. (C) and (D) Proliferation was
analysed by colony formation assay in IgR3 and Mel-RM cells that had been stably transduced with P53 shRNA (black bars) or control shRNA
(grey bars) and compared to their parental counterparts (white bars). Representative results are shown in (C) and quantification of 3
independent experiments is shown in (D) with the number of colonies expressed as a percentage of the control shRNA transduced cell lines
(mean ± SE). *p < 0.001 by students t-test.
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P53 and this resulted in increased proliferation in melano-
cytes, but not melanoma. These results further confirm
that P53 function is aberrant in melanoma and imply that
the disruption of P53-regulated pathways may be a contri-
buting factor in the progression of melanoma. This study
has identified several common P53-regulated targets that
are pro-survival (BIRC5, PLK2) and/or are necessary for
proper control of cell cycle progression (CCNB2, CCNE2,
CDC2, CDC25C, CDK6, CDKN2A) that may be involved
in this process. Moreover, the fact that inhibition of P53
resulted in decreased proliferation in melanoma suggests
that the altered functional activity of P53 may promote
tumour development and progression in melanoma, rather
than suppress it. In this regard, there is evidence suggest-
ing that P53 can protect cells from apoptosis. Almost 40
target genes, regulated by P53 have been shown to exert
anti-apoptotic effects, suggesting that P53 can transcrip-
tionally activate pro-survival pathways including those
involved in the repair of damaged DNA, cell cycle arrest
as well as those involved in the response to oxidative stress
[43,44]. Furthermore, there have been reports demonstrat-
ing that cells lacking functional P53 were more susceptible
to cell death induced by DNA-damaging agents [45-51].
The results presented herein suggest that P53 in mela-
noma, in the absence of any exogenous genotoxic stress,
has not only lost its ability to control proliferation, but
may indeed promote melanoma cell division. Although
these results are in contrast to other reported studies on
the role of p53 in melanoma progression [34,42], this chal-
lenges the notion that P53 is acting as a tumour suppres-
sor in melanoma. In agreement with the current studies, it
has been reported that P53 expression increases with mel-
anoma progression and depth of tumour invasion, and
that it is associated with worse prognostic features [5,32].
This was also noted by Terzian et al in their mouse model
where P53 expression was shown to increase in TP-ras
0/+
mice in the progression from nevi to melanoma, where
there was a tendency for rapidly growing melanomas to
express high levels of P53 [32].
The reasons for the functional aberration of P53 in mel-
anoma described in the current study are unclear. In parti-
cular instances, abnormal P53 function has been
associated with a failure to up-regulate particular P53 tar-
get genes due to a variety of factors, including loss of
adaptor proteins, deregulation of co-factors, or expression
of proteins that inhibit the transcription of particular tar-
get genes [19,20,52,53]. However, with the exception of
BRCA1, CDKN2A and CHEK1 which are known to
enhance the cell cycle regulatory function of P53 [36,37],
no other cofactors/regulators of P53 activity were altered
in melanoma that could describe the lack of effect
observed on P53 target genes as a result of P53 inhibition.
Several factors may be involved in these changes. We have
previously reported that small isoforms of P53, Δ40P53
and P53b, were highly expressed in melanoma cell lines
when compared to normal cells and were associated with
inhibition and enhancement respectively, of P53-depen-
dent regulation of P21 and PUMA expression following
treatment with Cisplatin [16]. P53b has also been shown
to induce senescence [54]. The expression of these iso-
forms may modulate the constitutive P53-dependent regu-
lation of these and other P53-dependent target genes. The
activity of P53 in response to stress stimuli is tightly regu-
lated by numerous post-translational modifications [55].
In particular, wild-type P53 in melanoma cells has been
shown to be highly phosphorylated compared to normal
cell lines and this would be expected to alter/impair its
function in melanoma [18,56]. In addition, mono-methyla-
tion of P53 at Lys 370 has been shown to repress P53-
mediated transcriptional regulation and apoptosis induc-
tion in H1299 cells [57]. Most recently, several studies
have shown that the regulation of microRNAs miR-34a,
miR-34b and miR-34c by P53 is vitally important for the
regulation of P53-dependent apoptosis and cellular prolif-
eration, with loss of mir-34a observed in several human
cancers [58]. Whether these factors can account for the
aberrant function of P53 in melanoma as observed in the
current study awaits further investigation.
Conclusions
In summary, this study has shown that not only is the
mRNA expression of P53 target genes aberrant in mela-
noma, but that P53 has lost the ability to regulate its tar-
get genes, particularly those involved in cell cycle control
and apoptosis. In fact the mRNA expression of these
genes resembles that in melanocytes in which P53 has
been knocked down by shRNA. The consequence of
alterations in the P53 target genes observed in this study
are altered growth/proliferation and a potential failure to
elicit appropriate responses to apoptotic-inducing sti-
muli, such as chemotherapy. The gene expression results
and studies on melanoma cell growth have provided pro-
vocative evidence that the P53 pathway in melanoma
rather than acting as a tumour suppressor, may promote
melanoma proliferation and progression. It remains now
to identify the factor(s) responsible for the aberrant func-
tion of this transcription factor in melanoma.
Additional material
Additional file 1: Supplementary Tables. Contains Supplementary
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Additional file 2: Figure S1: Inhibition of P53 abolishes P21
expression. The expression of P53 and P21 was analysed by western
blotting in whole cell lysates from Mel-RM and IgR3 cells stably
transduced with P53 shRNA or control shRNA and treated with CDDP (10
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determined to ensure equal loading. Results are representative of 3
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